The Numbers
Sydney cancer medtech Lumonus closed an additional $3m on top of its $25m Series B announced last November. Total raise: $28m. Brandon Capital and Investible joined the round, led by Aviron Investment Management.
Founded in 2024, the company has moved fast: 280,000+ cancer treatments consulted through their platform, 75,000+ treatment plans automated. They are live in the US, Australia, and Europe.
What This Means for Sales
CEO Keith Hansen was specific about where the money is going: "expand the US go-to-market and clinical success teams." That is startup speak for hiring AEs and customer success managers to sell into US health systems.
Healthcare sales is a different beast. Long cycles, complex stakeholders, regulatory hoops. If you have sold into hospital systems or medical device companies, Lumonus will likely be hiring for that experience. US expansion at Series B usually means 4 to 8 sales hires over the next 12 months.
The Product
Lumonus sells AI-powered workflow automation for radiation oncology. Their flagship products, Lumonus AI Physician and Lumonus AI Dosimetry, help clinicians plan cancer treatments faster. The pitch: cancer treatment has advanced, but the admin systems have not kept pace.
For sales teams, the value prop is efficiency: reduce time clinicians spend on treatment planning, improve accuracy, scale capacity. Healthcare buyers care about patient outcomes and operational costs. This product addresses both.
What We Don't Know
Comp details. Lumonus has not posted roles publicly yet, so no data on OTE, base splits, or quota structure. Healthcare sales comp typically runs lower than SaaS (think $140k-$180k OTE for mid-market AE roles), but equity at Series B medtech can be meaningful if they exit.
US expansion from an Australian base also raises questions about remote work, visa sponsorship, and territory structure. Worth watching their careers page over the next quarter.
Why It Matters
Healthtech hiring picked up in Q1 2026 after a slow 2025. Series B companies with real traction and US revenue are the ones actually hiring. If you are in healthcare sales or looking to break into medtech, companies like Lumonus are where the roles are opening up.
Oncology Ventures backed their seed round in March 2025, then doubled down here. That is a signal: investors see enterprise traction, not just pilot programs.